Treatment for use in a mass casualty event where thrombocytopenia or platelet loss is a major concern.
Active Definitive Contract Awarded Last action
- Contract number
- 75A50122C00065
- Awardee
-
Amgen USA Inc. UEI XPGNQMXHP493
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $839,875,190
Award facts
- Opportunity
-
- Therapeutic for treatment of Thrombocytopenia arising from H-ARS Pre-Solicitation · 75A50122R00021 · Posted Jun 15, 2022
- Contract value 85% obligated
-
- $839,875,189.59 Current, with exercised options
- $982,693,989.59 Potential, with all options
- Completion date 41% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Thousand Oaks, CA 91320, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $65,996,183 | |
| Supplemental Agreement for work within scope | $59,988,838 | |
| Exercise an Option | $89,975,028 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $128,996,651 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $204,858,569 | |
| Other Administrative Action | $0 | |
| Original award | $290,059,920 |
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Amgen USA Inc. for treatment of thrombocytopenia in mass casualty events resulting from acute radiation syndrome on September 30, 2022, with a ceiling value of $982.69 million and ultimate completion on September 29, 2032.
The contract is firm fixed price with no set-aside. The originating solicitation, posted June 15, 2022, sought an FDA-approved thrombopoietin receptor agonist using Project BioShield funds to treat thrombocytopenia arising from hematopoietic acute radiation syndrome. The therapeutic must increase survival in adults and pediatric patients exposed to myelosuppressive radiation doses and be effective when administered 24 or more hours post-radiation exposure. The procured therapeutic will be delivered to the Strategic National Stockpile and maintained as vendor managed inventory.
Place of performance is Thousand Oaks, CA. The contract exercise includes option period 4A valued at $65.70 million.
In fiscal year 2024, Amgen USA Inc. invoiced $204.8 million across 0.4 FTEs and 729 contractor hours, with a derived government-paid hourly rate of $280,888.83. The awardee self-performed all reported hours without subcontractors.
Quick answers
Who was awarded contract 75A50122C00065?
75A50122C00065 was awarded to Amgen USA Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2022.
How much is contract 75A50122C00065 worth?
The government has obligated $839,875,190 on 75A50122C00065. Its potential value, with all options, is $982,693,990.
Was contract 75A50122C00065 competed?
The extent of competition for 75A50122C00065 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award